Turning Pennies into dollars (Pink Sheets: KGLJ), (OTCBB: DORB), (Pink Sheets: SGCP), (OTCBB: WWAT).

For more info: http://kgli.realpennies.com

Kingslake Energy, Inc. (Pink Sheets: KGLJ) (Wed, February 13th, 2008, 8:42am ET) Kingslake Energy, Inc. announces a four-point growth strategy. The natural gas exploration and development company's current projects are located in the prolific Appalachian Basin. The area encompasses Kentucky, Tennessee, West Virginia, and Virginia. Kingslake holds strategic oil and gas leases in Kentucky covering 20,000 acres, more or less. The natural gas rich Devonian Shale formation underlies the entire lease area.

"We have embarked on an aggressive four-point growth strategy focused on acquiring and developing promising natural gas leases while maintaining our financial strength," commented James R. Pagnum, president of Kingslake Energy, Inc. "We believe that adherence to these four principles will guide us as we continue to expand our portfolio of oil and gas properties in our mission to create sustainable, long-term growth."

The four-points of Kingslake's growth plan are:

Identify and Develop Unconventional Resources

Explore in High-potential, Proven Basins

Ensure Financial Discipline and Flexibility

Growth by the drill bit

ABOUT KINGSLAKE ENERGY INC.

Kingslake Energy, Inc. plans to become significant presence in the multi-billion dollar US natural gas exploration and production market. The Company explores and drills in the prolific Appalachian Basin, an area encompassing Kentucky, Tennessee, West Virginia, and Virginia.

For more info: http://dorb.realpennies.com

DOR BioPharma, Inc. (OTCBB: DORB) (Wed, February 13th, 2008, 7:00am ET) DOR BioPharma, Inc. ("DOR" or "The Company"), a late-stage drug development company, announced today that positive results for orBec (oral beclomethasone dipropionate or oral BDP) in preventing serious lung injury in patients with gastrointestinal Graft-versus-Host disease (GI GVHD), will be presented this afternoon by Jason W. Chien, MD of the Fred Hutchinson Cancer Research Center (FHCRC) at the annual Tandem Bone Marrow Transplant Meeting of the American Society for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry in San Diego. The presentation is entitled "Preservation of pulmonary diffusing capacity with oral beclomethasone dipropionate: Results from two randomized, placebo-controlled trials in allogeneic graft recipients," published in Biology of Blood and Marrow Transplantation (Volume 14, Number 2, Supplement 2). DOR is also the Sponsor of the GVHD Working Committee at the conference on Thursday, February 14.

The pulmonary data, collected by DOR in response to a specific FDA request as part of its New Drug Application (NDA) review last summer, included a comparison of patients enrolled at FHCRC in two randomized, double-blind, placebo-controlled clinical trials for the treatment of patients with acute GI GVHD. Sixty patients had been randomized to orBec and the same number to placebo. Serial Pulmonary Function Tests (PFTs) at day 80 were available from 44 and 50 patients on placebo and orBec , respectively.

Significantly fewer patients randomized to orBec (55%) had deterioration of pulmonary diffusing capacity by transplant day 80, compared to placebo (79%), p=0.02. Clinical pulmonary events from the time of randomization to 200 days afterwards were reviewed by Dr. Chien of the FHCRC Pulmonary and Critical Care Medicine Section while blinded to the randomization assignment; no patient randomized to orBec developed a non-infectious pulmonary problem during this interval, compared to 4 patients on placebo.

These data suggest that orBec (oral BDP) may have a protective effect on early decline in pulmonary diffusing capacity, which commonly occurs by day 80 after transplant because of interstitial lung injury, and that this effect is accompanied by prevention of clinical pulmonary events such as Idiopathic Pneumonia Syndrome and Bronchiolitis Obliterans. It is hypothesized that these beneficial effects on the lungs were due to delivery of the potent immunosuppressive 17-BMP (an active metabolite of BDP) to the lungs via GI mucosa, portal vein, and pulmonary artery.

"The observations presented today in San Diego are intriguing and may lead to the development of new applications of oral BDP in a host of pulmonary inflammatory disorders having significant market opportunity beyond the GI area where we are currently in late-stage development," said Christopher J. Schaber, PhD, President and Chief Executive Officer of DOR. "We will continue to secure intellectual property in this new arena and to begin evaluating the possibilities for future clinical development."

George B. McDonald, MD, Head of the Gastroenterology/Hepatology Section at the FHCRC, inventor of orBec and an expert medical advisor to DOR, stated, "When we reviewed adverse event data from the pivotal Phase 3 trial of orBec for treatment of GI GVHD following hematopoietic cell transplantation, we noted a complete absence of non-infectious pulmonary infiltrates in patients in the orBec arm, compared to 18% in the placebo arm. These infiltrates are caused by inflammation of the lungs, most likely from the donor's immune cells. This observation led to the hypothesis that orBec (oral BDP), through its potent metabolite 17-beclomethasone monopropionate (17-BMP), delivered to the pulmonary artery via the gut and portal circulation, preserves lung function after allogeneic transplantation. Data presented at the Tandem Bone Marrow Transplant meeting suggests that this hypothesis is true, as significantly fewer orBec patients from a 120 randomized, single-center patient cohort had deterioration of pulmonary diffusing capacity by transplant day 80 compared to placebo, and none of 60 orBec patients had a non-infectious pulmonary event during a 200-day observation period, compared to 4 of 60 patients in the placebo arm. These non-infectious pulmonary events are significant causes of mortality after transplantation."

Dr. McDonald continued, "While the dominant effect of oral BDP is in the gastrointestinal mucosa, where it is significantly more effective than placebo in treating GVHD, some of its active metabolite, 17-BMP, reaches the pulmonary vasculature before being cleared from the systemic circulation. Thus, oral BDP may prevent pulmonary interstitial inflammation and subsequent lung injury. This beneficial effect of BDP could be useful not only in the setting of allogeneic hematopoietic cell transplantation, but as a potential treatment for a long list of pulmonary inflammatory conditions for which effective treatments are lacking."

For more info: http://sgcp.realpennies.com

Sierra Gold Corporation (Pink Sheets: SGCP) (Tue, February 12th, 2008, 8:30am ET) Sierra Gold Corporation, announced today that after four and a half years of research and exploration, the Company has extracted and sold the first-ever kilogram of alluvial gold from its holdings in the West African nation of Sierra Leone. Proceeds from the sale of the initial gold production are being used for continuing operations and will facilitate the purchase of customized equipment that will allow SGCP to advance its alluvial operation and commence the 'hard rock' phase of gold production.

Sierra Gold CEO Doug Evans commented on the progress of the company: ''The extraction and sale of our first gold production validate our years of research and exploration. Needless to say, we are extremely excited that the company has entered the production phase.'' Mr. Evans added, ''Our alluvial production, coupled with our soon-to-be initiated hard rock production, should provide significant returns on invested capital throughout the second half of 2008 and beyond. We look forward to sharing our successes with shareholders along the way.''

For more info: http://wwat.realpennies.com

WorldWater & Solar Technologies Corp. (OTCBB: WWAT) (Wed, February 13th, 2008, 3:01am ET) WorldWater & Solar Technologies Corp., developer and marketer of proprietary high-power solar systems, today announced that it has raised $35.64 million from The Quercus Trust ("Quercus") in a private placement of 20,000 shares of WorldWater Series F Convertible Preferred Stock at a price of $1,782.00 per share. Each share of the Series F Convertible Preferred Stock is convertible into 1,000 shares of WorldWater common stock. Quercus also received warrants to purchase 29 million additional shares of common stock at an exercise price of $1.815. Complete terms of the transaction will be described in a Form 8-K to be filed with the Securities and Exchange Commission.

"Thanks to the steadfast commitment of the Quercus Trust, WorldWater now has the funds critical to drive future growth," said Quentin T. Kelly, Chairman and CEO. "A portion of the financing will be utilized to complete the construction of our 50 MW production plant in Texas, which is vital to the many large awards we are now pursuing. The funds will also be used to hire staff, support global expansion, and bolster our R&D. WorldWater is clearly positioned for a strong 2008 and, with the acquisition of ENTECH now complete, ramping up to meet the rapidly-developing demand for solar energy worldwide."

Prior to February 8, 2008, The Quercus Trust and its affiliates owned shares of WorldWater common stock and preferred stock convertible into shares of WorldWater common stock representing approximately 11.5% of the equity ownership in the Company on a fully diluted basis. With this agreement, the Quercus Trust and its affiliates will own approximately 24.1% of the equity ownership in WorldWater on a fully diluted basis.

(Pink Sheets: SLND), (OTCBB: DORB), (PINK SHEETS: MVBY), (Nasdaq: KONG).

RealPennies.com: Turning Pennies into dollars: (Pink Sheets: SLND), (OTCBB: DORB), (PINK SHEETS: MVBY), (Nasdaq: KONG).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://slnd.realpennies.com

Solar Night Industries (Pink Sheets: SLND) (January 3, 2008) a renewable energy company formed to accelerate the adoption of Modern Energy Solutions, introduces the Solar Synapse(TM), a product, sales and marketing program designed to capitalize on the burgeoning demand for renewable energy alternatives among potential new homeowners. According to a recent Roper survey commissioned by Sharp Electronics Corporation, nearly 90 percent of Americans think that solar electricity should be an option for all new home construction. Three-quarters of survey respondents perceive solar power to be more important than ever, evidence that Americans recognize the value of solar as a modern, renewable form of energy.

The Solar Synapse Pre-Wire Kit is part of an overall program designed to empower homeowners to add energy efficiency in the future. The Kit, installed during construction, will prepare a new home for adding photovoltaic solar panels (electricity) at some future date. With new federal, state and local subsidies changing and the price of solar panels projected to halve in the next five years, the timing is perfect to make these new homes "solar ready" now. The program includes marketing materials to help the builder sell Pre-Wire Kits and provides a post-purchase activity for the new homeowner. After closing, new owners can go to the Solar Synapse (TM) site to register their kit. They will receive a copy of a "The Homeowner's Guide to Renewable Energy," plus they qualify to receive a Modern Energy Plan(TM) from SNI for their home. The revolutionary Modern Energy Plan(TM) is a customized plan that will tell them the cost to complete the total solar system, plus, educate the consumer regarding the incentives in their area.

Solar Night is expanding the Solar Synapse(TM) product rollout via a network of Manufacturer's Representatives' from the building and renewable energy segments. For more information, go to www.SolarSynapse.com.

For more info: http://dorb.realpennies.com

DOR BioPharma, Inc. (OTCBB: DORB) announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Oral BDP (beclomethasone dipropionate) for the treatment of pediatric Crohn's disease.

The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition to providing a seven year term of market exclusivity for Oral BDP upon final FDA approval, orphan drug designation also positions DOR to be able to take advantage of a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug Application for Oral BDP, and certain tax credits.

Oral BDP is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP has been marketed in the United States and worldwide since the early 1970s as the active pharmaceutical ingredient in inhalation products for the treatment of patients with allergic rhinitis and asthma. BDP is also the active ingredient in orBec , currently in development by DOR for the treatment and prevention of Graft-versus-Host disease (GVHD).

"The FDA's decision to grant Oral BDP Orphan Drug Designation for the treatment of pediatric Crohn's disease signifies an important step for DOR as we begin to expand our pipeline with Oral BDP into other important indications beyond GVHD," stated Christopher J. Schaber, PhD, President and CEO of DOR BioPharma. "We anticipate that pediatric Crohn's disease will be the first of several new Orphan Drug Designations both in the US and in Europe as we work to maximize the global value of our Oral BDP and orBec franchise. We believe that Oral BDP has the potential to be of significant benefit to pediatric Crohn's disease patients."

For more info: http://mvby.realpennies.com

My Vintage Baby, Inc. (PINK SHEETS: MVBY) a unique children's apparel company, announced today that its 2008 Spring Fashion Line will once again be available in select Neiman Marcus Children's Departments. "We are pleased that Neiman Marcus has once again chosen to include our garments in their children department's selection. Our first shipment for Spring 2008 to Neiman Marcus took place in late November and was followed up with a second delivery in December," stated Jessica Wiswall, CEO of My Vintage Baby.

Wiswall reported that Neiman Marcus selected twelve garments utilizing styles from both My Vintage Baby and Leopard Daisy. Neiman Marcus' selection will focus on toddler sizes, and Ms. Wiswall and My Vintage Baby received the coveted Earnie Award for Design Excellence in October 2007 for this size range.

For more info: http://kong.realpennies.com

KongZhong Corporation (Nasdaq: KONG) one of China's leading providers of wireless value-added services and a wireless media company providing news, content and mobile advertising services through its wireless Internet sites, announced today that it has signed a strategic alliance agreement with China Sports Industry Group Co., Ltd. ("CSIG"). Listed on Shanghai Stock Exchange of China, CSIG is China's largest public company in the sports industry and has the General Administration of Sports of China as its dominant shareholder. CSIG's business activities include organizing commercial sports tournaments, operating sports arenas and fitness centers, selling sports apparatus and goods, and more.

Under the agreement, KongZhong and CSIG will become strategic partners and jointly explore business opportunities for developing sports-related content for mobile phones, including wireless value-added services and wireless Internet sites.

Nick Yang, President of KongZhong, said, "We are happy about the strategic alliance with CSIG. The year 2008 is China's Olympic year and sports year. As people increasingly use their cell phones to enjoy their favorite sports, cooperation between CSIG and KongZhong can provide China's over 500 million cell phone users with easier access to sports-related content through their cell phone screens. We expect this strategic alliance to generate fruitful results for both CSIG and KongZhong in 2008 and future years. We also expect to enter into additional cooperative relationships with other players in the sports industry to develop our wireless value-added services and wireless Internet business in the 2008 Olympic year."

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com